Total
0
Shares
Neurotech International (ASX:NTI) - CEO, Peter Griffiths - The Market Herald
CEO, Peter Griffiths
Source: Accedian
  • Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global
  • The proprietary cannabis strains will be used to treat neurological disorders such as autism, epilepsy and ADHD
  • Genetic profiling from Dolce seedlings have shown high levels of specific cannabinoids and low levels of THC which benefit children with neurological disorders
  • These strains compliment Neurotech's Mente portable headband device which helps children with autism to relax and focus
  • Company shares have soared 60 per cent in the green and are trading for 1.6 cents each

Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.

The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.

Dolce is an Australian developer of medicinal cannabis with proprietary genetics that are sourced from 13 rare landrace chemovars and bolstered over the last two decades using selective breeding techniques.

Recent profiling of leaf cuttings from 650 seedlings of Dolce genetics showed high levels of cannabinoids CBG, CBC, CBN and CBDV. Recent studies have shown the potential for these cannabinoids to target neurological disorders.

A key feature of Dolce's strains is plant profiles with less than 0.3 per cent THC on average.

This is important, as Neurotech is focused on cannabis options for children with autism without the potential psychoactive effects of tetrahydrocannabinol (THC).

"With more evidence pointing to the potential for certain cannabinoids to help treat neurological disorders, it makes sense for us to explore this possibility through this agreement with leading cannabis genetics breeder Dolce and we are excited to get started on this research over the coming months," Chairman Mark Davies said.

The company hopes to achieve a combined approach to autism treatment by potentially combining Dolce's cannabis strains with its own Mente device. Mente is a portable headband that helps children with autism to relax, regulate and focus.

Project pathway

Neurotech has designed a three-stage program to investigate Dolce's cannabis strains in treating neurological disorders.

Dolce plans to engage ACS Laboratories, a leading cannabis testing lab, to undergo genetic profiling of selected cannabis strains.

The studies will include dose-response studies, upper level of toxicity assessments, mechanism of action profiling and selecting top candidates.

Small-scale human clinical trials will also be conducted with a leading Australian University.

The third stage will comprise product formulation and final dose profiling to be done alongside Medipharm Australia.

Company shares have soared 60 per cent in the green and are trading for 1.6 cents each just before market close.


Subscribe


NTI by the numbers
More From The Market Herald
Volpara Health Technologies (ASX:VHT) - Group CEO, Dr Ralph Highnam - The Market Herald

" Volpara Health Technologies (ASX:VHT) appoints Katherine Singson as CEO of U.S. subsidiary

Volpara Health Technologies (VHT) has appointed Katherine Singson as CEO of its U.S. subsidiary Volpara Solutions.
Alterity Therapeutics (ASX:ATH) - CEO & Chairman, Geoffrey Kempler - The Market Herald

" Alterity Therapeutics (ASX:ATH) confirms safety profile of MSA drug

Alterity Therapeutics (ATH) says new independent data has confirmed the safety profile of its ATH434 drug.
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) falls short of $3M entitlement offer target

Wellness group OBJ (OBJ) isn’t looking too well, after only securing offers for 37 per cent of new shares offered during a recent
Antisense Therapeutics (ASX:ANP) - Managing Director, Mark Diamond - The Market Herald

" Antisense Therapeutics (ASX:ANP) submits muscular drug to FDA

Antisense Therapeutics (ANP) has submitted its Duchenne muscular dystrophy (DMD) treatment, ATL1102, to the U.S.